Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus STILPHOSTROL.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen